DPP-4 inhibitors
B Ahren - Best Practice & Research Clinical Endocrinology & …, 2007 - Elsevier
Inhibition of dipeptidyl peptidase 4 (DPP-4) is a novel treatment for type-2 diabetes. DPP-4
inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases
levels of active GLP-1. This increases insulin secretion and reduces glucagon secretion,
thereby lowering glucose levels. Several DPP-4 inhibitors are in clinical development. Most
experience so far has been with sitagliptin (Merck; approved by the FDA) and vildagliptin
(Novartis; filed). These are orally active compounds with a long duration, allowing once-daily …
inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases
levels of active GLP-1. This increases insulin secretion and reduces glucagon secretion,
thereby lowering glucose levels. Several DPP-4 inhibitors are in clinical development. Most
experience so far has been with sitagliptin (Merck; approved by the FDA) and vildagliptin
(Novartis; filed). These are orally active compounds with a long duration, allowing once-daily …